Atogepant
A calcitonin gene-related peptide (CGRP) receptor antagonist taken by mouth that blocks CGRP signaling, a key driver of migraine pain and sensitization. It is approved as a preventive treatment to reduce the frequency of episodic and chronic migraines.
Molekularmasse
603,5000 g/mol
LogP
3,40
TPSA
104,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
InChI
InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
Molecular Formula
C29H23F6N5O3
HBD / HBA
2 / 11
Rotierbare Bindungen
4
Schwere Atome
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A calcitonin gene-related peptide (CGRP) receptor antagonist taken by mouth that blocks CGRP signaling, a key driver of migraine pain and sensitization. It is approved as a preventive treatment to reduce the frequency of episodic and chronic migraines.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Atogepant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3991065. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 72163100. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="atogepant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/atogepant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/atogepant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/atogepant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="atogepant"></drugfyi-drug>